Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial .One reason is that forecasting the economy is nearly impossible, as none of us can look into the future. All we can do is work based on current data and developments, which isAnalyst’s Disclosure: I/we have a beneficial long position in the shares of ODFL, FIX, CP either through ...

CHICAGO, May 2, 2025 /PRNewswire/ --As previously announced, TDS will hold a teleconference on May 2, 2025, at 9:00 a.m. CDT. Listen to the call live via the Events & Presentations page of investors.tdsinc.com.Telephone and Data Systems, Inc. (NYSE:TDS) reported total operating revenues of $1,154 million for the first quarter of 2025, versus $1,262 million for the same period one year ago. Net income (loss) attributable to TDS common shareholders and related diluted earnings (loss) per share were $(10) mill ...

ATHENS, Greece, April 30, 2025 (GLOBE NEWSWIRE) -- EuroHoldings Ltd. (NASDAQ: EHLD) (“EuroHoldings” or the “Company”) an owner and operator of ocean-going vessels and provider of seaborne transportation, announced today that, following its spin-off from Euroseas Ltd. on March 18th of this year, its Board of Directors has initiated a comprehensive review of strategic alternatives to maximize shareholder value. These alternatives include, among other possibilities, a potential sale of all or part of the Compa ...

Core Viewpoint - Cellectar Biosciences, Inc. is exploring a full range of strategic alternatives to enhance stockholder value, including potential mergers, acquisitions, partnerships, and licensing arrangements [1][2]. Company Overview - Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on developing proprietary drugs for cancer treatment, utilizing its Phospholipid Drug Conjugate™ (PDC) delivery platform [4]. Product Pipeline - The company's lead product, iopofosine I 131, is designed for targeted delivery of iodine-131 and has been studied in Phase 2b trials for multiple myeloma and CNS lymphoma [5][6]. - Other significant assets include CLR 225, targeting solid tumors like pancreatic cancer, and CLR 125, aimed at triple negative breast, lung, and colorectal cancers [5]. Strategic Evaluation Process - The company has engaged Oppenheimer & Co. Inc. as its exclusive financial advisor to assist in evaluating strategic alternatives, with no set timetable for completion [1][3]. - There are no guarantees that any transaction will result from this evaluation process [3].

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial .So far, this year has been quite something, as we have been bombarded by geopolitical and macroeconomic headlines almost on a daily basis. Especially the tariff announcement caused these risks to explode, as Mark Malek, chief investment officer at Siebert, perfectly summarized:A ...

FRISCO, Texas, April 29, 2025 (GLOBE NEWSWIRE) -- Stryve Foods, Inc. (OTC: SNAX) (“Stryve” or the “Company”), an emerging healthy snacking company focused on high-protein, air-dried meat snacks, today announces that it has engaged in a formal review process to evaluate potential strategic alternatives aimed at maximizing shareholder value while securing capital to support its accelerating growth in demand. Over the last two years, Stryve has made significant progress in transforming its operations and drivi ...

SS&C Technologies Holdings, Inc. (NASDAQ:SSNC) Q1 2025 Earnings Conference Call April 24, 2025 5:00 PM ET Company Participants Chand Madaka - Investor Relations Bill Stone - Chairman and Chief Executive Officer Rahul Kanwar - President and Chief Operating Officer Brian Schell - Chief Financial Officer Conference Call Participants Jeff Schmitt - William Blair Peter Heckmann - D.A. Davidson Companies Dan Perlin - RBC Capital Markets Surinder Thind - Jefferies Michael Infante - Morgan Stanley Andrew Schmidt - ...

Core Viewpoint - Enzo Biochem, Inc. has initiated a strategic review process to explore options for maximizing shareholder value, including potential transactions and capital returns [1][2][3] Group 1: Strategic Review Process - The Board of Directors has formed a special committee of independent directors, named the Strategic Committee, to evaluate various strategic alternatives [1][2] - The Strategic Committee has engaged BroadOak Capital Partners as financial advisor and BakerHostetler LLP as legal counsel to assist in the evaluation process [2] - There is no set timetable for the review process, and the Board has no biases towards any potential strategic alternatives at this time [3] Group 2: Company Operations and Market Position - Enzo Biochem has over 45 years of experience in the life sciences sector, primarily through its Life Sciences division, which offers a wide range of products including antibodies, genomic probes, and assays [4] - The company’s proprietary products and technologies are integral to translational research and drug development, covering areas such as cell biology and genomics [4] - Enzo Biochem has recently transferred its stock listing from NYSE to OTC, continuing to trade under the ticker symbol "OTCQX: ENZB" [5]

For Immediate ReleaseChicago, IL – April 17, 2025 – Today, Zacks Equity Research Equity Philip Morris International Inc. (PM) , Altria Group, Inc. (MO) and Turning Point Brands, Inc. (TPB) .Industry: TobaccoLink: https://www.zacks.com/commentary/2449632/3-tobacco-stocks-worth-watching-on-robust-industry-trendsThe Zacks Tobacco industry is shifting focus toward smoke-free alternatives, driven by rising consumer health awareness and stricter regulations on traditional cigarettes. Leading companies like Philip ...

EverCommerce Inc. (NASDAQ:EVCM) Q4 2024 Earnings Conference Call March 13, 2025 5:00 PM ET Company Participants Brad Korch - Senior Vice President & Head, Investor Relations Eric Remer - Chairman & Chief Executive Officer Ryan Siurek - Chief Financial Officer Matt Feierstein - President Evan Berlin - Chief Executive Officer, EverHealth Conference Call Participants Bhavin Shah - Deutsche Bank Alex Sklar - Raymond James Mike Richards - RBC Capital Markets Aaron Kimson - Citizens Kirk Materne - Evercore ISI Op ...